SI-BONE, Inc. (NASDAQ:SIBN) Director Jeffrey W. Dunn Sells 1,609 Shares

SI-BONE, Inc. (NASDAQ:SIBN) Director Jeffrey W. Dunn sold 1,609 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.43, for a total value of $19,999.87. Following the sale, the director now owns 20,431 shares of the company’s stock, valued at $253,957.33. This trade represents a 7.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

SI-BONE Stock Performance

Shares of SIBN opened at $12.15 on Thursday. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. SI-BONE, Inc. has a 52-week low of $11.76 and a 52-week high of $21.70. The company has a 50-day simple moving average of $13.85 and a 200-day simple moving average of $14.25.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on SIBN shares. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of SI-BONE in a research report on Wednesday. Morgan Stanley cut their price target on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Finally, Truist Financial lifted their price objective on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $23.00.

Institutional Investors Weigh In On SI-BONE

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of SI-BONE by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 2,463,501 shares of the company’s stock worth $40,328,000 after acquiring an additional 43,670 shares during the period. Bessemer Group Inc. boosted its position in SI-BONE by 79.8% during the first quarter. Bessemer Group Inc. now owns 37,859 shares of the company’s stock worth $620,000 after purchasing an additional 16,800 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in SI-BONE by 7.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 20,494 shares of the company’s stock valued at $336,000 after purchasing an additional 1,372 shares during the last quarter. Bellevue Group AG increased its position in shares of SI-BONE by 810.5% in the first quarter. Bellevue Group AG now owns 1,139,956 shares of the company’s stock valued at $18,661,000 after buying an additional 1,014,756 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC raised its stake in shares of SI-BONE by 13.8% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 1,060,937 shares of the company’s stock worth $17,368,000 after buying an additional 128,702 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.